COMPOUND

MOLECULAR TARGET

PATHWAY

CONDITIONS

Ref

PR73 (only preclinical models)

PTG300 (Rusfertide)

LJPC-401

FPN

Hepcidin mimetics, ferroportin inhibitors

B-THALASSEMIA, HAEMOCHROMATOSIS

[93] [94] [95]

Anticalins

PRS-080

Hepcidin

Hepcidin antagonist,

ferroportin stimulation

HEALTHY VOLUNTEERS,

CHRONIC KIDNEY DISEASE

[96]

Sodium-glucose cotransporter 2 inhibitors

Hepcidin, Erythropoietin

Reduction hepcidin pathway

ferroportin stimulation

ANEMIA, IRIDA , HF

[97] [98] [99]

Tmprss6

Anti Matriptase-2 (antibody)

Increased emojuvelin pathway

Increased hepcidin pathway

DISORDERS OF EYTHROPOIESIS AND IRON HOMEOSTASIS (IRON OVERLOAD AND DEFECTS)

[100] [101]

H5F9-AM8 (preclinical models)

Emojuvelin

(antibody)

Reduced emojuvelin

Pathway Reduction hepcidin pathway

IRON IN MOUSE LIVER AND TUMOR XENOGRAFTS

[102]

Anti BMP,

Anti cytokines Interleukin (IL)-6 IL-1β, anti TGF 23

Cytokines

STAT 3- and SMAD/

hepcidin pathway inhibitors

ANEMIA OF INFLAMMATION

[103] [104] [105]

Vamifeport (VIT-2763)

FPN

ferroportin inibition

HEALTHY VOLUNTEERS

[106] [107]

GDF 15

Cytokines (IL6-1)

Reduction BMP/hepcidin pathway

IDA

[108]

SPIRONOLACTONE

Hepcidin

Suppression hepcidin expression

IDA

[109]

IMATINIB

Hepcidin

Suppression hepcidin expression

IDA

[109]

HEPARIN

Hepcidin/BMP

hepcidin antagonist

IDA

[110]

ERYTROFERRONE

BMP6 inibition

Reduction hepcidin pathway

IDA

[111]